Ting Ting is currently working at Ultragenyx as an Associate Director in Analytical Development. Prior to this, Ting Ting worked at Luye Pharma USA Ltd. specializing in gene therapy, particularly focusing on AAV gene therapy for ocular and neurological indications. Ting He's previous experience includes research at the University of North Carolina at Chapel Hill, where they worked on AAV vector development in CNS disorders, as well as at the Oklahoma Medical Research Foundation focusing on brain tumor metabolism and molecular cancer markers using in vivo small animal MR imaging. Ting Ting holds a Ph.D. in Neuroscience from the University of Oklahoma Health Sciences Center and has a background in Pharmacology and Clinical Medicine from Anhui Medical University.
March 1, 2024 - present
September, 2021